NCT05785156 Diagnostic and Prognostic Value of New Quick Tests of Action Slowing in Stroke and in Cognitive Neurodegenerative Disease
| NCT ID | NCT05785156 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Condition | Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 129 participants |
| Start Date | 2021-07-16 |
| Primary Completion | 2027-07-16 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 129 participants in total. It began in 2021-07-16 with a primary completion date of 2027-07-16.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A large series of recent studies have documented the frequency of the slowing of the action in brain diseases, especially vascular and neurodegenerative diseases. In stroke, the predictive value of action slowing at the acute phase for predicting post-stroke functional outcome remains poorly investigated. In neurodegenerative diseases, the diagnostic relevance of the slowing at the prodromal stage remains unknown and this diagnostic requires new tests. Finally, in terms of anatomical determinants, few studies have studied the determinants of action slowing. The objectives of this project are to Determine the diagnostic and prognostic value of action slowing assessed with new quick tests in patients with acute stroke (Neurovascular Unit) and cognitive neurodegenerative disorders (Alzheimer Disease (AD), Lewy Body disease (LBD), Fronto Temporal lobar degeneration (FTLD), Cortico Basal Degeneration (CBD) and Progressive Supra Nuclear Palsy (PSNP)) and to define the lesion determinants with VBM and VLSM
Eligibility Criteria
Inclusion Criteria: * Patients between 40 and 85 years old, * French native language, * Social Security affiliation. * University Memory Clinic for: Mild severity disorder (MMSE\> 19) or major severity disorder related to AD : Albert 2011 criteria ; McKhann 2011 * to MCL according to McKeith criteria * to FTLD according to Rascovsky 2011 criteria * BBD according to Armstrong's criteria * related to PSP according to Höglinger criteria Exclusion Criteria: * Mental retardation or guardianship * Previously diagnosed dementia * Other current or past brain condition * severe head trauma * epilepsy prior to stroke still requiring previous treatment * Parkinson disease, multiple sclerosis... * brain tumor or brain radiation therapy * Current or past schizophrenia or psychosis * Active or past psychiatric disorders requiring a stay\> 2 days in a specialized environment * Contra indication to MRI * Comorbidity with life expectancy \<1 year * Comorbidity affecting cognition in particular: * Alcohol (\> 3 glasses / day) or history of alcohol withdrawal syndrome * opiate or cocaine addiction or opiate withdrawal syndrome * renal failure (dialysis or creatinine clearance \<30) * hepatic failure (spontaneous INR\> 1.5 or PT \<60%) * respiratory failure requiring oxygen therapy * heart failure (orthopnea\> 2 pillows) * persistent vigilance disturbances (NIHSS1a score ≤1) * cancer with paraneoplastic syndrome * treatment with gold salts, D Penicillamine or other treatment with cognitive effect * Patient under guardianship or curators or private under public law * Pregnant and / or lactating wom
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05785156 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 85 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05785156 currently recruiting?
Yes, NCT05785156 is actively recruiting participants. Contact the research team at roussel.martine@chu-amiens.fr for enrollment information.
Where is the NCT05785156 trial being conducted?
This trial is being conducted at Amiens, France.
Who is sponsoring the NCT05785156 clinical trial?
NCT05785156 is sponsored by Centre Hospitalier Universitaire, Amiens. The trial plans to enroll 129 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.